[{"address1": "Clarence Thomas Building", "address2": "P.O. Box 4649 Road Town", "city": "Tortola", "zip": "VG1110", "country": "British Virgin Islands", "phone": "203 221 7378", "website": "https://www.portagebiotech.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.", "fullTimeEmployees": 7, "maxAge": 86400, "priceHint": 4, "previousClose": 0.282, "open": 0.255, "dayLow": 0.2261, "dayHigh": 0.2635, "regularMarketPreviousClose": 0.282, "regularMarketOpen": 0.255, "regularMarketDayLow": 0.2261, "regularMarketDayHigh": 0.2635, "beta": 95.435, "forwardPE": -0.46730772, "volume": 304578, "regularMarketVolume": 304578, "averageVolume": 345964, "averageVolume10days": 354210, "averageDailyVolume10Day": 354210, "marketCap": 4807609, "fiftyTwoWeekLow": 0.2, "fiftyTwoWeekHigh": 3.95, "fiftyDayAverage": 0.27804, "twoHundredDayAverage": 1.07332, "currency": "USD", "enterpriseValue": -927393, "floatShares": 10532616, "sharesOutstanding": 19784400, "sharesShort": 59188, "sharesShortPriorMonth": 8377, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.003, "heldPercentInsiders": 0.38824, "heldPercentInstitutions": 0.10941, "shortRatio": 0.19, "shortPercentOfFloat": 0.0046, "impliedSharesOutstanding": 19784400, "bookValue": 1.618, "priceToBook": 0.1501854, "lastFiscalYearEnd": 1680220800, "nextFiscalYearEnd": 1711843200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -144898000, "trailingEps": -8.52, "forwardEps": -0.52, "lastSplitFactor": "1:100", "lastSplitDate": 1591228800, "enterpriseToEbitda": 0.049, "52WeekChange": -0.9272455, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PRTG", "underlyingSymbol": "PRTG", "shortName": "Portage Biotech Inc.", "longName": "Portage Biotech Inc.", "firstTradeDateEpochUtc": 1009981800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c85b618a-5b14-3e35-9d8d-d4e5ddb2236b", "messageBoardId": "finmb_233586353", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.243, "targetHighPrice": 7.0, "targetLowPrice": 7.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 5341000, "totalCashPerShare": 0.27, "ebitda": -18928000, "totalDebt": 275000, "quickRatio": 1.993, "currentRatio": 2.775, "debtToEquity": 0.878, "returnOnAssets": -0.0913, "returnOnEquity": -1.4519099, "freeCashflow": -8471250, "operatingCashflow": -15857000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]